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Alzheimer’s disease (AD) is a fast growing neurodegenerative disorder of the central nervous system 
and anti-oxidants can be used to help suppress the oxidative stress caused by the free radicals that are 
responsible for AD. A series of selected synthetic indole derivatives were biologically evaluated 
to identify potent new antioxidants. Most of the evaluated compounds showed significant to modest 
antioxidant properties (IC50 value 399.07 140.0±50 µM). Density Functional Theory (DFT) studies were 
carried out on the compounds and their corresponding free radicals. Differences in the energy of the 
parent compounds and their corresponding free radicals provided a good justification for the trend found 
in their IC50 values. In silico, docking of compounds into the proteins acetylcholinesterase (AChE) and 
butyrylcholinesterase (BChE), which are well known for contributing in AD disease, was also performed 
to predict anti-AD potential.
Uniterms: Alzheimer’s disease. Antioxidant compounds. Chronic diseases. Density Functional Theory. 
Molecular docking. Computational studies. DPPH assay. Indole derivatives. Acetylcholinesterase (AChE). 
Butyrylcholinesterase (BChE).
A doença de Alzheimer (DA) é uma doença neurodegenerativado sistema nervoso central, em rápido 
crescimento, e antioxidantes ajudam a suprimir o estresse oxidativo causado por radicais livres, 
responsávies pela DA. Avaliou-se, biologicamente, série de derivados sintéticos de indol selecionados 
para identificar novos antioxidantes. A maioria dos compostos avaliados apresentou de significativa a 
boa propriedade antioxidante (valor de IC50 399,07140.0 ± 50 µM). Eftuaram-se estudos de Teoria do 
Funcional de Densidade (DFT) com os compostos e os seus correspondentes radicais livres. As diferenças 
de energia entre os compostos protótipos e os radicais livres correspondentes proporcionaram boa 
justificativa para a tendência encontrada nos seus valores de IC50. O ancoramento in silico dos compostos 
com a acetilcolinesterase (AChE) e com a butirilcolinesterase (BChE), que contribuem para a DA, foi, 
também, realizado para prever o seu potencial anti-DA.
Unitermos: Doença de Alzheimer. Compostos antioxidantes. Doenças crônicas. Teoria do Funcional 
de Densidade. Ancoramento molecular. Estudos computacionais. Ensaio de DPPH. Derivados do indol. 
Acetilcolinesterase (AChE). Butirilcolinesterase (BChE).
M. Yar, M. Arshad, A. Farooq, M. A. Gilani, K. Ayub, A. Ejaz, A. Kumar, I. Ninomiya54
INTRODUCTION
A l z h e i m e r ’s  d i s e a s e  ( A D )  i s  a  c o m p l e x 
neurodegenerative disorder of the central nervous system 
and the most common form of dementia in elderly people 
(Scarpini, Scheltens, Feldman, 2003). Affecting over 
20 million people worldwide (Suh, Suslick, Suh, 2005), 
it is characterized by progressive loss of cognitive and 
memory, speech loss and personality changes and is 
one of the major causes of admissions to nursing homes 
(Wilson et al., 2007). Moreover, the cholinergic hypothesis 
postulates that a decrease in acetylcholine (ACh) levels 
within the brain causes gradual neurodegeneration and 
leads to AD (Francis et al., 1999).
The oxidative stress caused by free radicals has 
been shown to be a main contributor to the development 
of Alzheimer’s disease (Floyd, Hensley, 2002). Currently 
drugs designed to treat AD are based on the improvement 
of cholinergic neurotransmission. This increase in 
neurotransmission is attained through the inhibition of an 
enzyme responsible for acetylcholine hydrolysis, AChE, 
and also by the inhibition of human plasma BChE (Silva 
et al., 2006). The first approved drugs for the management 
of the disease were the cholinesterase inhibitors tacrine, 
donepezil, rivastigmine, and galanthamine (Figure 1). 
These drugs helped increase neurotransmission at 
cholinergic synapses in the brain and thereby improve 
cognition (Giacobini, 2004).
The practical efficiency of these acetylcholinesterase 
inhibiting drugs (AChE-I) for AD treatment remains 
controversial. Recent AD trials concluded that AChE-I 
therapies are not cost effective and show detrimental side 
effects. These problems have led to discontinuation in 
certain cases, as seen with tacrine (Petersen et al., 2005). 
For these reasons the interest in the development of new 
and potent cholinesterase inhibitors has increased in the 
last few years.
A number of studies have shown that in elderly 
people the antioxidant defense system loses its capacity 
to neutralize oxidative species, and this oxidative 
stress can act as a possible reason for the initiation 
and progression of AD (Floyd, Hensley, 2002). In the 
brains of patients with AD, according to oxidative and 
nitrosylative damage hypothesis, reactive nitrogen 
species (RNS) and reactive oxygen species (ROS) 
play important roles in the initiation and promotion of 
neurodegeneration. Clinical studies have shown the 
beneficial effects of high-dose antioxidants (Sokura 
et al., 2005). Thus, drugs that specifically scavenge 
oxygen radicals may have a particular therapeutic 
efficacy (Tan et al., 2003), and several antioxidants 
have been tested in clinical trials (Klatte et al., 2003). 
To design a new anti-AD agent, with potential AChE 
and BChE inhibitory activities, molecular modeling 
techniques are of great significance (Sarojini et al., 2010, 
2011).
Indole alkaloids are well known due to their 
extensive biological importance (Inman, Moody, 2013; 
Yar et al., 2014b) including AChE (Monte-Millán et al., 
2006; Ismail et al., 2012; Munoz-Ruiz et al., 2005) and 
BChE (Boga et al., 2011; Jakubowska et al., 2012; Yar et 
al., 2014a) inhibition activities. Compounds containing 
indole skeleton were also found to be the dual binding 
site AChE inhibitors, which in turn has a potential in 
disease modifying agents (Munoz-Ruiz et al., 2005) 
(Figure 2, a and b). Thus, there is a great deal of interest 
to develop dual binding site AChE inhibitors as a means 
to control AD (Monte-Millán et al., 2006; Yar et al., 
2014a). Tacrine-melatonin hybrids (Figure 2, c), which 
were potent inhibitors of human AChE and showed high 
oxygen radical absorbance capacity, were also synthesized 
(Franco, Isabel, 2006).
Among alkaloids, indole alkaloids represent one 
of the most interesting class of compounds, especially 
pentacyclic natural indole alkaloids such as reserpine 
(Figure 3). Reserpine was isolated from Rauwolfia 
serpentina and is regarded an important pharmacological 
agent due to its extensive use in the treatment of 
hypertension and mental disorders (Chatterjee, Pakrashi, 
Werner, 1956; Woodson et al., 1957; Lucas et al., 1963; 
Monachino, 1954).
Such promising biological potential of indole 
FIGURE 1 - Known drugs as cholinesterase inhibitors.
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FIGURE 2 - Known indole derivatives as potent AChE inhibitors.
FIGURE 3 -The chemical structure of reserpine.
alkaloids has prompted us to synthesize and biologically 
evaluate a series of indole derivatives (Table I) to identify 
potent novel antioxidants. In this paper we report the 
synthesis of indole derivatives 1-4, their DPPH scavenging 
activities and DFT studies based on the calculations of the 
energy differences of the indole parent molecules and their 
corresponding free radicals. These energy differences are 
correlated with the IC50 values for the first time ever. In the 
present study, the binding modes of the newly synthesized 
indole alkaloid 2 (predicted to have the most anti-oxidant 
potential in the tested series) with AChE and BChE are 
also demonstrated.
MATERIAL AND METHODS
Chemistry
Indole derivatives 1-4 were prepared by following 
our reported procedures (Yar et al., 2012). For detailed 
synthetic methods and characterization of the compounds 
1, 2, 3 and 4, please see our previous paper (Yar et al., 
2012). The structures of the compounds 1-4 are shown 
in Table I. 
Antioxidant activity
DPPH (1, 1-diphenyl-2-picryl hydrazyl radical) free 
radical scavenging activity: The reaction mixture containing 
5 μL of test sample (1 mM in DMSO) and 95 μL of DPPH 
(sigma, 300 μM) in ethanol was employed. The reaction 
mixture was taken in a 96-well micro liter plate (molecular 
devices, USA) and incubated in Elisa at 37 °C for 30 min. 
At the end of the incubation period the absorbance was 
measured at 515 nm using a spectrophotometer. Percent 
radical scavenging activity was determined by comparison 
with a DMSO treated control (Table I). IC50 values showed 
concentrations of compounds to scavenge 50% DPPH 
radicals. BHA (3-t-butyl-4-hydroxy anisole) was used as 
positive control. All the chemicals used were of analytical 
grade purchased from Sigma-Aldrich USA.
Molecular docking
The crystal structure of AChE (PDB Id: 4EYZ) 
bound to donepezil and BChE (PDB Id: 4B0O) bound 
to benzyl pyridinium-4-methyltrichloroacetimidate 
were used for the docking studies. Dock Prep (Lang et 
al., 2009) module was used in Chimera (Pettersen et al., 
2004) to delete solvent water molecules while retaining the 
water molecules within 5 Å of the bound ligand. Adding 
hydrogens and repairing the truncated side chains was 
done by using rotamer libraries (Dunbrack et al., 2002). 
The prepared protein was saved in pdbqt format using 
Autodock Tools 1.5.6 (Morris et al., 2009). The ligand 
coordinates were generated by using the molecular design 
program TorchV10lite (http://www.cresset-group.com/
products/torch/torchlite/) and smiles were converted to 
3D structure by using Openbabel (O’Boyle et al., 2011) 
version (2.3.1). The pdbqt files for ligands were prepared 
by Autodock Tools 1.5.6 by using default parameters. 
Kollman charges were added to the standard residues 
while Gasteiger charges were added to the ligands by 
using the ADT tools. AUTODOCK 4 (Morris et al., 2009) 
was used for docking calculations with a grid box size of 
40×40×40 and centered on the co-crystallized ligand. For 
validating the docking protocol, co-crystallized ligand was 
docked with RMSD from reference ligand as 0.44 and 1.48 
for donepezil and 15F, respectively. Docked poses were 
analyzed by using Autodock Tools 1.5.6 to get the best 
binding pose of compound 2a with the lowest binding 
energy and the best overlap with the co-crystallized ligand.
Computational studies
All calculations were performed with Gaussian 09 
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(Frisch et al., 2009). The geometries of the structures were 
optimized at hybrid B3LYP method (Becke, 1993; Lee et 
al., 1988) with 6-31G* basis set. The method and basis set 
chosen provided a nice balance between cost and accuracy. 
The geometries of the optimized structures were visualized 
using Marvin View (MarvinView 5.9.4. ChemAxon.2012).
RESULTS AND DISCUSSION
The whole series of compounds (1-4) shown in 
Table I were screened for their antioxidant activity. Among 
these compounds, 2 presented the highest activity with 
an IC50 value of 140.0 µM, while compound 3, in which 
an α, β-unsaturated double bond was converted into cis-
epoxide, showed the second highest activity with an IC50 
of 145.8 µM. As compared to the α, β-unsaturated ketone 
2, the activity of the β,γ-unsaturated ketone 1 was curtailed 
as its IC50 was found to be 178 µM. The possible reason for 
the lower activity in the case of compounds 3 and 1 could 
be due to the absence of conjugation in the ring E. When 
compound 2, bearing the α,β-unsaturated ketone, was 
converted into compound 4, which contained a methoxy 
group at the α-position, its activity was further decreased 
to IC50 358 µM. The results are summarized in Table I.
Computational studies
Computational studies were carried out to correlate 
the structure-activity relationship of the compounds 
(1-4) as shown in Figure 4. Triggered by the well-
established fact that in the DPPH assay scavenging of 
DPPH free radicals occurs by H-transfer from the radical 
scavengers, we became interested in correlating the ease 
of formation of free radicals by the structures 1-4 with 
their corresponding IC50 values. Only the ring E offers the 
structural variation in all the four structures and hence it is 
expected to be responsible for the variations of IC50 values. 
The energies of the optimized structures 1-4 and their 
corresponding proposed free radicals were calculated. 
We thought that a free radical with higher energy would 
be more difficult to form. For this purpose we compared 
the energies of free radicals for each molecule with their 
parent molecule, Table I. It is noted that their differences 
justify the trend found in their IC50 values. The greater 
the energy difference between a free radical and its parent 
molecule the more difficult it is for the molecule to offer 
a proton to scavenge the DPPH free radical; hence the 
molecule must exhibit less oxidant potential and have a 
higher IC50 value as a consequence. Indole 4 shows the 
TABLE I - The quantitative estimation of antioxidant activity of the indole derivatives IC50 values are means of three independent 
experiments (Mean±SEM, n = 3)
Sr No.
% Scavenging 
activity of DPPH 
at 1000 µM
IC50 (µM)
Energy of parent 
molecule (au)
Energy of free 
radical (au)
Energy difference 
between parent 
molecule and 
radical (kcal/mol)
Structures
1 79.08 178.0 -1035.34 -1034.71 392.70
2 79.9 140.0 -1035.31 -1034.71 375.65
3 85.7 145.8 -1110.54 -1109.92 386.85
4 74.2 358 -1149.86 -1149.24 392.90
BHA 92.1 44.2±.02
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highest IC50 value (less potent) due to the highest energy 
difference. The lowest energy difference and lowest IC50 
value were observed for the molecule 2, thus it had the 
highest antioxidant potential. In the structures 2 and 4, only 
one energetically favorable site (C-35) is available from 
where hydrogen abstraction would take place. In indole 
1, a hydrogen atom abstracted from the position C-44 
shows more stability and this is consistent with the IC50 
value observed experimentally. Similarly, for the indole 3, 
hydrogen abstraction is believed to occur from C-28. This 
ultimately leads to ring opening of the epoxide.
FIGURE 4 - Optimized geometries of the optimized compounds 1-4.
Molecular modelling
AChE docking
All the compounds (1-4) were docked in the crystal 
structure of AChE (PDB Id : 4EYZ) by using AUTODOCK 
4 (Morris et al., 2009; Pettersen et al., 2004). The docking 
conformation of compound 2 overlaps very well with 
the crystal structure conformation of donepezil bound to 
Acetylcholinesterase (PDB : 4EYZ) (Figure 5).
The N-H in the indole forms a hydrogen bond with 
Tyr 124. There are three π-π interactions present such as 
FIGURE 5 - (a) Docked binding mode of indole derivative 2 with AChE (PDB : 4EYZ); (b) The ligand molecule 2 buried in the 
AChE active pocket.
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with Tyr 341, Phe 338 and Trp 86. Compound 2 mostly 
forms hydrophobic interactions in addition to 1 hydrogen 
bond within the active site. The docking binding energy 
is -10.75 kcal/mol as compared to -11.72 kcal/mol for 
donepezil.
BChE docking
Similarly, we docked compound 2 in the crystal 
structure of BChE (PDB Id: 4B0O). The docked pose of 
2 overlaps very well with the bound benzyl pyridinium-
4-methyltrichloroacetimidate (PDB Id: 15F) (Figure 6). 
The free energy of binding was estimated to be −8.86 
kcal/mol and −6.60 kcal/mol for 2 and pyridinium-
4-methyltrichloroacetimidate (15F), respectively. 
Compound 2 forms 3 hydrogen bonds with Trp 82 and Trp 
440 on one side and the –OCH3 functional group forms 
hydrogen bond with water (W2013) on the other side. A 
dual binding site was not observed for this compound. 
The docking of ligand molecule 2 with AChE (PDB 
: 4EYZ) revealed that the binding energy is minimum and 
the inhibitor compound is completely enclosed within 
the active pocket. Correspondingly the docking of the 
same ligand molecule with BChE (PDB Id: 4B0O) is also 
minimum binding energy. Theoretically it is predicted 
that molecule 2 is docked well in both AChE and BChE.
CONCLUSIONS
In summary, we have synthesized and identified a 
series of indole derivatives as potent novel antioxidants. 
Computational studies were also performed. The ease 
with which the free radicals are formed could suggest a 
plausible reason for the trend found in their antioxidant 
potential. Among compounds 1, 2, 3, and 4, having IC50 
178.0, 140.0, 145.8 and 358.0 μM respectively, compound 
2 showed the most appreciable activity. In the future, these 
compounds may act as potential lead molecules in the field 
of potent antioxidant research. The theoretical calculations 
made can be applied to the design of new molecules with 
TABLE II -The docking results for ligand molecule 2 against AChE and BChE
Protein Compound H- bonds Binding Energy (kcal/mole) Protein Compound H- bonds
Binding Energy 
(kcal/mole)
AChE
1 1 ˗11.00
BChE
1 2 ˗8.48
2 1 ˗ 10.75 2 3 ˗ 8.86
3 2 ˗ 10.76 3 2 ˗ 8.19
4 1 ˗ 11.00 4 1 ˗ 8.50
Donepezil 1 -11.72
Benzyl pyridinium-
4-methyltrichloroa-
cetimidate
0 -6.60
FIGURE 6 -(a) Docked binding mode of indole derivative 2 with BChE (PDB : 4B0O); (b) The ligand molecule 2 buried in the 
BChE active pocket.
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greater potency and we are currently conducting research 
on this matter. In silico, docking of compounds into the 
proteins (Acetylcholinesterase and Butyrylcholinesterase), 
which are well known for contributing to AD disease, was 
also performed to predict their AChE and BChE inhibition 
potential. Among all of the compounds (1-4), compound 
2 showed the best inhibition of both AChE and BChE.
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